Neurogene Inc. (LSX:A3EX79) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of shares Closed: US$144M raised | Aug 11, 2026 |
| Public offering of shares of common stock and pre-funded warrants Update: about US$125M · US$30 a share · Leerink Partners +4 Dealers: Leerink Partners (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead), LifeSci Capital (co-lead), William Blair (co-lead) Use of proceeds: Fund clinical development and pre-commercial activities for NGN-401, working capital and general corporate purposes | Jul 1, 2026 |